Antonio Pierini

Hematologist. Bone Marrow Transplant specialist. Life enthusiast. Passionate about science. Junior Faculty @ University of Perugia.

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

Truly honoured to receive the 5th EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2025! It’s been a fantastic #CART25 congress in Strasbourg! @EHA_Hematology @TheEBMT

[Antonio Pierini @PieriniLab]

@ValentinOrtizMD @EHA_Hematology @TheEBMT Really deserved!!!

[Antonio Pierini @PieriniLab]

It was a privilege to be part of a fantastic #ash24 educational session on leukemia relapse after hsct together with ⁦@vago_luca⁩ and Sawa Ito.

[Antonio Pierini @PieriniLab]

Biology of post-transplant relapse: actionable features | Hematology, ASH Education Program | American Society of Hematology https://t.co/iiFnCiQfXY

[Tommaso Perini @Tom_Perini]

Really wonderful talk as usual @vago_luca
Congratulations for your amazing work!
#ASH24

[Anna Sureda @AnnaSureda5]

A dream that is already a reality! A true team effort! Thanks to all that have made it possible!! 💥💥🎉🎉

[Antonio Pierini @PieriniLab]

Very nice and interesting work at #ASH22 cannot wait for the manuscript!

[Shernan Holtan MD @sghmd]

Does #BMT age the hematopoietic system?

Yes, by 5-10 years, as estimated by loss of clonal diversity.

Also interesting that only ~30K stem cells engraft on average.

Great one, @doctor_msc 🙏

Fascinating fundamental work, with implications for donor selection. 👇

#ASH22

[AML Hub @AML_Hub]

Congress | #ASH22 @charliecraddock Queen Elizabeth Hospital, Birmingham, delivers a fascinating talk on MRD in AML and how it can affect transplant decision-making. They highlight the impact of MRD positivity on conditioning regimens, stem cell source, and maintenance therapy.

[Antonio Pierini @PieriniLab]

So cool to present last clinical data at #ASH2022.

[Antonio Pierini @PieriniLab]

#AIRC #AML #BMT #Treg

[Fondazione AIRC per la ricerca sul cancro @AIRC_it]

La ricerca di Antonio Pierini punta a rendere più efficace il trapianto di midollo. L’approccio descritto in uno studio finanziato da #AIRC ha ottenuto un aumento della sopravvivenza a 2 anni dal trapianto, dal 20 al 70 per cento.

#ricerca
https://t.co/Y74ReXNteT

[Antonio Pierini @PieriniLab]

https://t.co/hjHChHoS7l #AngelmanSyndrome #RareDisease

[Antonio Pierini @PieriniLab]

@RaffaellaGrecoM @SanRaffaeleMI @CiceriFabio @lupo_mt @vago_luca Congrats!!! Nice work @RaffaellaGrecoM

[Stem Cell Evidence @evidencestemc]

From this months' #StemCellEvidence Alert: Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for #AML @PieriniLab in @BloodAdvances
https://t.co/LeruTdbDWG #BMT #leusm

[Antonio Pierini @PieriniLab]

Cool! #science

[Science Magazine @ScienceMagazine]

“Begin universe.
Wait three minutes to enter.
Stay cool. Don’t react.”

Which #ChemHaiku is your favorite? https://t.co/pw6qmwLMN5 #HaikuPoetryDay

[Antonio Pierini @PieriniLab]

@IlariaIacobucc1 @BloodJournal @CMullighan @StJudeResearch Great work!!! Congrats!

[Blood Advances @BloodAdvances]

Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia https://t.co/lotVlzKHXM #AML

[Antonio Pierini @PieriniLab]

Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia https://t.co/eGHWvXvbLe…
Hard work, but finally out! A new transplant option for our patients! So proud! #transplant #Treg #AML #leukemia

[Antonio Pierini @PieriniLab]

Nuovo progetto AIRC per la lotta alle leucemie https://t.co/7ryqfY97Mw via @arquennet

[raffaellagreco @RaffaellaGrecoM]

https://t.co/qwsjcHetYo